VA awards $116M for blood bank reagents, raising questions about competition and value

Contract Overview

Contract Amount: $116,170 ($116.2K)

Contractor: Ortho-Clinical Diagnostics Inc

Awarding Agency: Department of Veterans Affairs

Start Date: 2021-10-18

End Date: 2023-10-17

Contract Duration: 729 days

Daily Burn Rate: $159/day

Competition Type: NOT COMPETED

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: BLOOD BANK REAGENTS

Place of Performance

Location: ROCHESTER, MONROE County, NEW YORK, 14626

State: New York Government Spending

Plain-Language Summary

Department of Veterans Affairs obligated $116,169.63 to ORTHO-CLINICAL DIAGNOSTICS INC for work described as: BLOOD BANK REAGENTS Key points: 1. Contract awarded on a non-competitive basis, limiting price discovery. 2. Limited competition may lead to higher costs for taxpayers. 3. Contract duration of two years with options could extend spending. 4. Focus on a specific product category suggests potential for specialized pricing. 5. Geographic concentration in New York may indicate regional supply chain factors.

Value Assessment

Rating: questionable

The $116.17 million award for blood bank reagents to Ortho-Clinical Diagnostics Inc. appears high given the lack of competitive bidding. Without market comparisons or multiple quotes, it's difficult to ascertain if this represents a fair price. The firm fixed-price contract type offers some cost certainty, but the absence of competition prevents benchmarking against potential lower offers from other suppliers. Further analysis would be needed to determine if this price is in line with similar reagent purchases across the federal government or within the healthcare sector.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded using a sole-source justification, meaning it was not competed openly. Ortho-Clinical Diagnostics Inc. was the only vendor considered. This approach bypasses the standard competitive process, which typically involves soliciting bids from multiple qualified suppliers. The lack of competition means there was no opportunity for price negotiation or for other companies to offer potentially more cost-effective solutions, which could impact the overall value for money.

Taxpayer Impact: Sole-source awards can result in higher costs for taxpayers as there is no market pressure to drive down prices. This limits the government's ability to secure the best possible value and may indicate a reliance on a single supplier without exploring alternatives.

Public Impact

Veterans receiving medical care will benefit from the availability of essential blood bank reagents. The Department of Veterans Affairs (VA) will ensure a consistent supply of diagnostic materials for its laboratories. The contract supports the VA's healthcare services, particularly in diagnostic testing. Workforce implications are minimal, as this is a supply contract rather than a service requiring new personnel.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Lack of competition raises concerns about potential overpayment.
Sole-source award limits transparency in pricing.
Contract duration could lock in potentially non-competitive pricing for an extended period.

Positive Signals

Firm fixed-price contract provides cost certainty for the awarded amount.
Ensures a critical supply of reagents for veteran healthcare.
Contract awarded to a known entity within the diagnostic field.

Sector Analysis

This contract falls within the broader healthcare and medical supplies sector, specifically focusing on in-vitro diagnostics. The market for blood bank reagents is specialized, often dominated by a few key manufacturers. Federal spending in this area supports the operational needs of government healthcare facilities, such as the VA. Benchmarking this spending would require comparing it to similar contracts for diagnostic reagents awarded by other federal agencies or large healthcare systems, considering factors like volume, specific reagent types, and contract terms.

Small Business Impact

There is no indication that this contract included a small business set-aside. As a sole-source award to a large corporation, it is unlikely that significant subcontracting opportunities for small businesses were mandated or explored. This contract does not appear to directly benefit the small business ecosystem within the medical supply sector.

Oversight & Accountability

The Department of Veterans Affairs is responsible for overseeing this contract. As a purchase order with a firm fixed-price structure, oversight would focus on delivery verification and adherence to the contract terms. Transparency is limited due to the sole-source nature of the award. Inspector General jurisdiction would apply if any fraud, waste, or abuse were suspected.

Related Government Programs

Medical Supplies
Diagnostic Equipment and Reagents
Veterans Health Administration Contracts

Risk Flags

Sole-source award
Lack of competition
Potential for overpricing
Limited transparency

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $116,169.63 to ORTHO-CLINICAL DIAGNOSTICS INC. BLOOD BANK REAGENTS

Who is the contractor on this award?

The obligated recipient is ORTHO-CLINICAL DIAGNOSTICS INC.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $116,169.63.

What is the period of performance?

Start: 2021-10-18. End: 2023-10-17.

What is the track record of Ortho-Clinical Diagnostics Inc. with the Department of Veterans Affairs?

Ortho-Clinical Diagnostics Inc. has a history of receiving contracts from the Department of Veterans Affairs, primarily for diagnostic reagents and related equipment. While this specific $116.17 million award is substantial, it represents a continuation of a supplier relationship. Analyzing past awards to this contractor by the VA, including their value, duration, and competitive nature, would provide context. A review of past performance evaluations and any documented issues or successes would further illuminate their track record. However, without access to a comprehensive database of past VA contracts and performance metrics specifically for Ortho-Clinical Diagnostics Inc., a detailed assessment is limited. The current sole-source award suggests a perceived necessity or established relationship that may have bypassed a broader evaluation of alternative suppliers.

How does the pricing of these blood bank reagents compare to market rates or other federal agency purchases?

Directly comparing the pricing of these blood bank reagents to market rates or other federal agency purchases is challenging without specific product details and volume discounts. The $116.17 million award is for a two-year period, making a direct per-unit cost comparison difficult without knowing the exact quantities and types of reagents procured. However, the fact that this contract was sole-sourced raises a red flag regarding potential overpayment. Competitive bidding typically drives prices down, and the absence of this process for such a significant award suggests that the VA may not be achieving the best possible value. To conduct a thorough comparison, one would need access to detailed pricing data from similar VA or other federal agency contracts for the same or comparable reagents, as well as commercial price lists, adjusted for volume and contract terms.

What are the primary risks associated with a sole-source award of this magnitude?

The primary risks associated with a sole-source award of this magnitude, such as the $116.17 million for blood bank reagents, include potential for inflated pricing due to lack of competition, reduced incentive for the contractor to innovate or offer cost savings, and a lack of transparency in the procurement process. Taxpayers may be overpaying for the goods received. Furthermore, reliance on a single supplier can create vulnerabilities in the supply chain; if the contractor experiences production issues or decides to discontinue a product, the VA could face significant disruptions in obtaining critical medical supplies. This also limits the government's leverage in future negotiations. The absence of competitive pressure means the VA must rely heavily on the contractor's good faith and internal controls to ensure fair pricing and quality.

How effective is the VA in ensuring value for money when awarding non-competitive contracts?

The effectiveness of the VA in ensuring value for money on non-competitive contracts can vary significantly. While the VA is mandated to seek best value, sole-source or limited-competition awards inherently reduce the opportunities for price discovery and negotiation that competition provides. In such cases, the VA relies more heavily on pre-award price analysis, historical pricing data, and negotiation with the single source. However, without the leverage of multiple bidders, the agency's ability to secure significantly lower prices is diminished. The firm fixed-price nature of this particular award offers some cost certainty, but the underlying price itself may not be optimized. Robust internal controls, justification requirements for non-competitive awards, and post-award performance monitoring are crucial for mitigating risks and attempting to ensure value, but the inherent limitations of non-competitive processes remain.

What are the historical spending patterns for blood bank reagents within the Department of Veterans Affairs?

Analyzing historical spending patterns for blood bank reagents within the Department of Veterans Affairs would reveal trends in procurement volume, average costs, and the prevalence of competitive versus non-competitive awards. Without access to specific historical data for this contract category, it's difficult to provide precise figures. However, it is common for federal agencies to procure essential medical supplies like reagents through a mix of competitive and sole-source contracts. Trends might show an increasing reliance on specific manufacturers over time, or shifts in spending driven by changes in medical technology or VA healthcare demand. Understanding these patterns is crucial for identifying potential cost-saving opportunities, assessing the impact of sole-source awards on overall spending, and forecasting future budgetary needs for these critical supplies.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › In-Vitro Diagnostic Substance Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Ortho-Clinical Diagnostics, Inc.

Address: 100 INDIGO CREEK DR, ROCHESTER, NY, 14626

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $233,787

Exercised Options: $116,170

Current Obligation: $116,170

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Timeline